Industry News

AqueSys raises $43.6 million in Series D financing

New and existing investors have enabled AqueSys to secure $43.6 million in Series D financing, according to a press release.

“AqueSys is very pleased to raise this significant round of financing with a premier group of venture capital and private equity partners who share our vision to significantly improve the glaucoma treatment paradigm through highly effective yet minimally invasive technology,” Ron Bache, AqueSys president and CEO, said in the release.

Existing investors include Accuitive Medical Ventures, The Carlyle Group, Longitude Capital, Rho Ventures and SV Life Sciences, according to the release.

AqueSys is developing Xen Gel Stent technology for treating glaucoma and has finished enrollment in its first U.S. Food and Drug Administration approved investigational device exemption study and begun enrollment in its second study using the technology, according to the release.

New and existing investors have enabled AqueSys to secure $43.6 million in Series D financing, according to a press release.

“AqueSys is very pleased to raise this significant round of financing with a premier group of venture capital and private equity partners who share our vision to significantly improve the glaucoma treatment paradigm through highly effective yet minimally invasive technology,” Ron Bache, AqueSys president and CEO, said in the release.

Existing investors include Accuitive Medical Ventures, The Carlyle Group, Longitude Capital, Rho Ventures and SV Life Sciences, according to the release.

AqueSys is developing Xen Gel Stent technology for treating glaucoma and has finished enrollment in its first U.S. Food and Drug Administration approved investigational device exemption study and begun enrollment in its second study using the technology, according to the release.